Replies to post #429727 on NorthWest Biotherapeutics Inc (NWBO)

[Nick119]

You didn't ask me, but there are many ground-breaking outcomes as part of this phase 3 trial's conclusion most notably:

-A change in how oncology trials are conducted in the future through the elimination of an unethical placebo group by use of historical controls.

-A disruption in the standard of care, initially for GBM, but setting a baseline for further disruption soon after for all solid tumor cancers.

These are the reasons for a peer-reviewed publication in a MAJOR, TOP-TIER (their words, not mine) medical journal.

The burden of ensuring all t's are crossed and i's are dotted in today's new covid world order (as exwannabe puts it) are a significant part of the reasons for the delay.

The end result will be alignment across all regulatory parties, the medical community, and patient advocacy groups for the perfect, irrefutable, ground-breaking treatment to change the outcomes of cancer patients world-wide.

[Horseb4CarT]

The company has repeatedly stated they are following the steps they have stated several times.

As to the delay, at least two knowledgeable posters have informed us that the steps can take times that add up and our so-called delay can fall within the estimated time range.

I’m in the stock among the longest and I agree it’s been extremely frustrating to wait this long after data lock for TLD. I think we’re very close now however I support the company’s approach of getting it right to maximize success.